MedTrace Logo

Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department

NCT02972502 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2018-10-23

Study results available
· View outcomes & findings →

Summary

Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of medication, is thought to act by affecting the dopamine 2 receptor in the brain.

By exploring haloperidol as an option for treatment, the investigators hope to discover a more efficient and effective medication for the treatment of non-traumatic headaches, thereby decreasing a patient's length of stay in the department and decreasing the rate of return visits for continued discomfort from the same headache. This study could lead to the increased usage of haloperidol as a first line agent in the treatment of prolonged headaches presenting to the ED.

Conditions

  • Headache, Migraine

Interventions

DRUG

Metoclopramide

Patients receive 10 mg of intravenous (IV) metoclopramide.

DRUG

Haloperidol

Patients receive 2.5 mg of IV haloperidol.

OTHER

Normal Saline

All patients receive a 1-liter bolus of normal saline (NS)

DRUG

Diphenhydramine

All patients receive 25 mg of intravenous (IV) diphenhydramine.

Sponsors & Collaborators

  • OhioHealth

    lead OTHER

Principal Investigators

  • Christopher Lloyd, D.O. · Attending Physician

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2017-04-24
Completion
2017-04-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02972502 on ClinicalTrials.gov